Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer

Official title

Phase II Trial of Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer

Overview

This is a trial studying patients with human papilloma virus (HPV) positive oropharyngeal cancer with tumors that can be removed via transoral surgery. Following surgery, patients will be classified as either low, intermediate, or high risk based on the characteristics of the tumors. Low risk patients (Arm S) will receive no further treatment after surgery. Intermediate risk patients (Arm RT) will be treated with Intensity Modulated Radiotherapy (IMRT) after surgery. High risk patients (Arm CRT) will receive a combination of IMRT and chemotherapy after surgery. Patients will be followed for up to five years after the completion of treatment.

Detailed description

This phase II trial is designed to rationally de-escalate adjuvant (Intensity Modulated Radiotherapy (IMRT) in the post-transoral surgery (TOS) setting in a study population consisting of patients with resectable oropharynx carcinoma, p16+ as confirmed by immunohistochemistry IHC, with a performance status (PS) of 0-1. Patients will be classified into one of three category/treatment groups (low-, intermediate-, and high-risk) according to their highest pathologically risk feature. Radiation will be given via an IMRT technique. For the high-risk patient group, a reduced, but slightly accelerated radiotherapy (RT) fractionation regimen of 50 Gy (HCC 18-034) in conjunction with cisplatin will be used compared to the standard 66 Gy and cisplatin. Low risk patients will transition to observation, intermediate risk patients will receive 30 Gy in 15 fractions of IMRT, and high risk patients will receive 50 Gy in 25 fractions (one day a week will include two treatments) plus 40 mg/m2 Cisplatin for 5 weeks. Patients who are not able to tolerate cisplatin will receive carboplatin instead.

Interventions

• Procedure therapeutic conventional surgery
  Transoral surgical resection of tumor(s).
• Other laboratory biomarker analysis
  Correlative studies
• Other quality-of-life assessment
  Ancillary studies.
• Radiation intensity-modulated radiation therapy
  Low-dose IMRT
• Drug Cisplatin
  Given IV.
• Drug Carboplatin
  Given IV

Primary outcome measures

• Recurrence-Free Survival (RFS) [Time frame: Up to 2 years (for cohort)]

Secondary outcome measures (12)

• Loco-regional control (at 1 year) [Time frame: Up to 1 year]
• Loco-regional control (at 2 years) [Time frame: Up to 2 year]
• Time to distant metastasis (at 1 year) [Time frame: Up to 1 year]
• Time to distant metastasis (at 2 years) [Time frame: Up to 2 years]
• Overall survival at 1 year [Time frame: Up to 1 year]
• Overall survival at 2 years [Time frame: Up to 2 years]
• Distribution of patients based on histologic risk features [Time frame: Up to 3 years]
• Assessment of PEG tube dependence [Time frame: At 1 year (post treatment)]
• Adverse Events Related to Treatment [Time frame: Up to 5 years]
• Quality of Life via FACT-HN [Time frame: Baseline (before treatment), at 4-8 weeks post-surgery, at 3 months, 6 months, 1 year, up to 2 years following treatment]
• MD Anderson Symptom Inventory-Head & Neck (MDASI-HN) [Time frame: Baseline (before treatment), at 4-8 weeks post-surgery, at 3 months, 6 months, up to 2 years following treatment]
• Modified Barium Swallow (MBS) rating [Time frame: Before treatment, at 4-8 weeks post-surgery, 6 months and 24 months following treatment]

Eligibility criteria

Inclusion criteria

• ECOG performance status of 0 or 1 or Karnofsky score 80-100.
• Preference is to register patients prior to surgery. However, if not registered prior to surgery, the patient can be registered prior to adjuvant therapy.
• Patients must have newly diagnosed, histologically or cytologically confirmed SCC or undifferentiated carcinoma of the oropharynx. Patients must have been determined to have resectable oropharyngeal disease. Patients with primary tumor or nodal metastasis fixed to the carotid artery, skull base or cervical spine are not eligible.
• Patients must be deemed eligible for a TOS procedure with no evidence of distant metastasis as determined by imaging studies. Metastatic disease may be evaluated using CT or PET/CT where appropriate; this can be performed with or without contrast. The following imaging is acceptable to evaluate the primary and regional disease:

• CT Neck (with contrast preferred but not required)
• PET/CT
• MRI Neck (contrast preferred but not required)
• Patients must have biopsy-proven p16+ oropharynx cancer; the histologic evidence of invasive squamous cell carcinoma may have been obtained from the primary tumor or metastatic lymph node. It is required that patients have a positive p16 IHC (as surrogate for HPV) status from either the primary tumor or metastatic lymph node.
• Carcinoma of the oropharynx associated with HPV as determined by p16 protein expression using immunohistochemistry (IHC) performed by a CLIA approved laboratory. Using p16 antibody obtained from Roche mtm laboratories AG (CINtec, clone E6H4) is recommended.
• No prior radiation above the clavicles.
• Patients with a history of a curatively treated malignancy must be disease-free for at least two years except for carcinoma in situ of cervix, melanoma in-situ (if fully resected), and/or non- melanomatous skin cancer.
• Patients with the following within the last 6 months prior to registration must be evaluated by a cardiologist and/or neurologist prior to entry into the study.

• Congestive heart failure > NYHA Class II
• CVA/TIA
• Unstable angina
• Myocardial infarction (with or without ST elevation)
• Patients must have acceptable renal and hepatic function within 4 weeks prior to registration

o For patients stratified following surgery and to concurrent chemotherapy (Arm CRT), calculated creatinine clearance must be > 60 ml/min using the Cockcroft-Gault formula

• In patients with a contraindication to cisplatin, carboplatin can be used at time of patient enrollment if they are allocated to ARM CRT.

Exclusion criteria

• No evidence of extensive or "matted/fixed" pathologic adenopathy on preoperative imaging.
• Patients must not need a microvascular (free flap) reconstruction. Women must not be pregnant or breast-feeding due to the teratogenicity of chemotherapy. All females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy. A female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).
• Patient must not have an intercurrent illness likely to interfere with protocol therapy or prevent surgical resection
• Patients must not have uncontrolled diabetes, uncontrolled infection despite antibiotics, or uncontrolled hypertension within 30 days prior to registration.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Non-randomized

Model

Parallel assignment

Masking

Open label

Primary purpose

Treatment

Study locations

United States · 1 center

• UPMC Hillman Cancer Center — Pittsburgh

Identifiers

NCT: NCT05388773 · HCC 22-030

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗